Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: evelobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2021 | $44.00 → $41.50 | Market Outperform | JMP Securities |
| 11/1/2021 | $12.00 | Neutral → Buy | Chardan Capital Markets |
| 6/23/2021 | $36.00 → $38.00 | Market Outperform | JMP Securities |
| 6/23/2021 | $28.00 | Overweight | Cantor Fitzgerald |
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
4 - Evelo Biosciences, Inc. (0001694665) (Issuer)
EFFECT - Evelo Biosciences, Inc. (0001694665) (Filer)
15-12G - Evelo Biosciences, Inc. (0001694665) (Filer)
S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)
S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)
8-K - Evelo Biosciences, Inc. (0001694665) (Filer)
POS AM - Evelo Biosciences, Inc. (0001694665) (Filer)
25-NSE - Evelo Biosciences, Inc. (0001694665) (Subject)
DEFA14A - Evelo Biosciences, Inc. (0001694665) (Filer)
DEF 14A - Evelo Biosciences, Inc. (0001694665) (Filer)
8-K - Evelo Biosciences, Inc. (0001694665) (Filer)
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 6076311. A live webcast of the event will also be available under "News and Events" in the Investors section of Eve
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7574834. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at h
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be ava
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously
Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously
Cantor Fitzgerald initiated coverage of Evelo Biosciences with a rating of Overweight and set a new price target of $28.00
Morgan Stanley reiterated coverage of Evelo Biosciences with a rating of Equal-Weight and set a new price target of $13.00 from $14.00 previously
Jefferies upgraded Evelo Biosciences from Hold to Buy and set a new price target of $18.00 from $11.00 previously
Chardan Capital reiterated coverage of Evelo Biosciences with a rating of Neutral and set a new price target of $15.00 from $10.00 previously
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Outperform and set a new price target of $36.00 from $27.00 previously
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial results and recent business highlights. Simba Gill, Ph.D., Evelo's Chief Executive Officer, said, "We are on track for a top line read
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the "Shares") at a purchase price of $2.31 per share, which would result in gross proceeds of approximately $25.5 million. The offering is being led by Evelo's founder, Flagship Pioneering, with participation from other new and existing investors. Evelo intends to use the net procee
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time today, June 29, 2023, after close of trading on The Nasdaq Global Select Market. The Company's common stock is expected to commence trading on a split-adjuste
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
- Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors. Dr. Severino and Mr. Fibig bring decades of drug development and commercialization leadership experience to Montai, where their expertise and support will be critical as the company advances its artificial intelligence (AI) platform to enable the predictable discovery of breakthrough small molecules for chronic disease. "I'm thri
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in-class bioplatform during the past two years CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer (CFO), Cameron Trenor, M.D., as Vice President and Head of Translational Medicine, and Anjali Kumar, Ph.D., as Vice President, Head of Business Development. In addition, Parul Doshi, M.B.A., has been promoted to Chief Data Officer in recognition of her significant contribution to the development of Cellarity and her leadership in the implementation of an efficient and scalable data infrastructure to support Cellarity's unique approach to drug creation. Cellarity is fundamentally redesignin
The Company's Proprietary Address, Navigate, Design (AND)™ Platform Produces Medicines that are Better, Safer and More Tolerable for Patients After Two Years of Development, Flagship Commits $50 Million to Advance the Company's Platform and Build an Initial Pipeline of Therapeutics Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the site of disease. Flagship has initially committed $50 million to advance the company's Address, Navigate, Design (AND)™ Platform and develop an initial pipeline of medicines across a range of disease areas. "Most
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13D/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13D/A - Evelo Biosciences, Inc. (0001694665) (Subject)
SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
- Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors. Dr. Severino and Mr. Fibig bring decades of drug development and commercialization leadership experience to Montai, where their expertise and support will be critical as the company advances its artificial intelligence (AI) platform to enable the predictable discovery of breakthrough small molecules for chronic disease. "I'm thri
Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo
AVENTURA, Fla. and NATICK, Mass., June 7, 2022 /PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on empowering natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately. "In the past year, Cytovia has graduated into a fully-integrated global biotech with R&D and cell manufacturing capabilities. As
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities. Werner most recently served as Wo
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.